Rebecca Olin, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address400 Parnassus Avenue, #A448
San Francisco CA 94117
Phone415-353-2063
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of PennsylvanniaM.D.2003School of Medicine
    University of PennsylvaniaM.S.C.E.2009School of Medicine
    Collapse Awards and Honors
    University of California San Francisco2018Health Value Improvement Program's "Best Partnerships Across Initiatives"
    University of California San Francisco2018Heme/BMT Value Improvement Program's "Great Save Award"
    American Society of Hematology2008Travel Award
    American Society of Hematology2005Trainee Award
    University of Pennsylvania2003Dr. Spencer Morris Prize for graduating first in medical school class
    University of Pennsylvania2002Botelho Prize for Excellence in Basic Science for highest score on the first medical licensure exam
    University of Pennsylvania2002Alpha Omega Alpha, early induction
    Amherst College1999Phi Beta Kappa

    Collapse Overview 
    Collapse Overview
    Dr. Rebecca Olin is a hematologist who specializes in bone marrow transplantation in adults. Her expertise encompasses treating acute leukemia, myelodysplastic and myeloproliferative disorders (conditions in which the bone marrow makes too many white blood cells) and aplastic anemia (a condition in which the body doesn’t make enough new blood cells).

    In her research, Olin has a particular interest in studying how best to treat blood cancers in older patients, some of whom may require a bone marrow transplant.

    Olin earned her medical degree from the Perelman School of Medicine at the University of Pennsylvania and was elected to the Alpha Omega Alpha Honor Medical Society. She completed a residency in internal medicine as well as a fellowship in hematology and oncology at the Hospital of the University of Pennsylvania, serving as chief fellow for one year. She also has a master's degree in clinical epidemiology, with a focus on medical decision making, from the University of Pennsylvania.

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy. Blood Adv. 2024 Oct 22; 8(20):5297-5305. Hoff FW, Blum WG, Huang Y, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Archer KJ, Patel PA, Collins RH, Baer MR, Duong VH, Arellano ML, Stock W, Odenike O, Redner RL, Kovacsovics T, Deininger MW, Zeidner JF, Olin RL, Smith CC, Foran JM, Schiller GJ, Curran EK, Koenig KL, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus SG, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Borate UM, Mims AS, Byrd JC, Madanat YF. PMID: 39110987.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. 701P Multicenter analysis of first-line (1L) regimens (BEP vs VIP) in patients (pts) with non-seminomatous germ cell tumors (NSGCTs) who subsequently underwent high-dose chemotherapy (HDCT). Annals of Oncology. 2024 Sep 1; 35:s540. Ebrahimi EH, Shodiya SM, Maldonado ME, Othman OT, Barragan-Carrillo BR, Li LX, Rock RA, Tripathi TA, Pal PS, Dorff DT, Zhumkhawala ZA, Hoeg HR, Oliai OC, Olin OR, Mei MM, Chehrazi-Raffle CA. .
      View in: Publisher Site   Mentions:
    3. Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies. Cancer Med. 2024 Jul; 13(14):e70028. DiNardo CD, Olin R, Wang ES, Skikne B, Rosenthal J, Kumar P, Sumi H, Hizukuri Y, Hong Y, Patel P, Seki T, Duan T, Lesegretain A, Andreeff M. PMID: 39030997; PMCID: PMC11258486.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    4. Multicenter analysis of high-dose chemotherapy (HDCT) regimens for the treatment of patients (pts) with recurrent germ cell tumors (GCTs). Journal of Clinical Oncology. 2024 May 29; 42(16_suppl):5039-5039. Chehrazi-Raffle CA, Shodiya SM, Maldonado ME, Othman OT, Ebrahimi EH, Barragán Carrillo BR, Li LX, Rock RA, Tripathi TA, Pal PS, Dorff DT, Zhumkhawala ZA, Hoeg HR, Oliai OC, Olin OR, Mei MM. .
      View in: Publisher Site   Mentions:
    5. A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML. Blood Adv. 2024 01 23; 8(2):429-440. Cai SF, Huang Y, Lance JR, Mao HC, Dunbar AJ, McNulty SN, Druley T, Li Y, Baer MR, Stock W, Kovacsovics T, Blum WG, Schiller GJ, Olin RL, Foran JM, Litzow M, Lin T, Patel P, Foster MC, Boyiadzis M, Collins RH, Chervin J, Shoben A, Vergilio JA, Heerema NA, Rosenberg L, Chen TL, Yocum AO, Druggan F, Marcus S, Stefanos M, Druker BJ, Mims AS, Borate U, Burd A, Byrd JC, Levine RL, Stein EM. PMID: 37871309; PMCID: PMC10827405.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    6. Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial. Clin Lymphoma Myeloma Leuk. 2024 Jun; 24(6):364-374. Konopleva MY, Dail M, Daver NG, Garcia JS, Jonas BA, Yee KWL, Kelly KR, Vey N, Assouline S, Roboz GJ, Paolini S, Pollyea DA, Tafuri A, Brandwein JM, Pigneux A, Powell BL, Fenaux P, Olin RL, Visani G, Martinelli G, Onishi M, Wang J, Huang W, Dunshee DR, Hamidi H, Ott MG, Hong WJ, Andreeff M. PMID: 38378362.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    7. It's All in the Timing. N Engl J Med. 2023 Sep 07; 389(10):940-947. Beagle AJ, Sunwoo BY, Olin RL, Schwartz BS, Block BL. PMID: 37672698.
      View in: PubMed   Mentions:    Fields:    
    8. Association of geriatric measures and global frailty with cognitive decline after allogeneic hematopoietic cell transplantation in older adults. J Geriatr Oncol. 2023 11; 14(8):101623. Huang LW, Shi Y, Andreadis C, Logan AC, Mannis GN, Smith CC, Gaensler KML, Martin TG, Damon LE, Boscardin WJ, Steinman MA, Olin RL. PMID: 37678052; PMCID: PMC11101048.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    9. Evaluation of venous thromboembolism prophylaxis protocol in hematopoietic cell transplant patients. Bone Marrow Transplant. 2023 11; 58(11):1247-1253. Lee A, Badgley C, Lo M, Banez MT, Graff L, Damon L, Martin T, Dzundza J, Wong M, Olin R. PMID: 37626267; PMCID: PMC10622316.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    10. Value of embedded palliative care: outpatient palliative care and health care utilization for patients with hematologic malignancies. Blood Adv. 2023 07 11; 7(13):3146-3149. Tsang M, Bischoff K, Schoenbeck KL, Berry K, O'Riordan D, Fakhri B, Wong SW, Shah N, Olin R, Andreadis C, Vieaux J, Cohen E, Lopez NS, Mannis GN, Rabow M. PMID: 36809787; PMCID: PMC10362539.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    11. Lack of disease control remains a major barrier to transplant for older patients with AML. Bone Marrow Transplant. 2023 09; 58(9):1054-1056. Jeng MY, Kong D, Rajalingam R, Lin RJ, Olin RL. PMID: 37353571; PMCID: PMC11022831.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    12. Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates. Blood Adv. 2023 06 13; 7(11):2360-2363. Saliba AN, Kaufmann SH, Stein EM, Patel PA, Baer MR, Stock W, Deininger M, Blum W, Schiller GJ, Olin RL, Litzow MR, Lin TL, Ball BJ, Boyiadzis MM, Traer E, Odenike O, Arellano ML, Walker A, Duong VH, Kovacsovics T, Collins RH, Shoben AB, Heerema NA, Foster MC, Peterson KL, Schneider PA, Martycz M, Gana TJ, Rosenberg L, Marcus S, Yocum AO, Chen T, Stefanos M, Mims AS, Borate U, Burd A, Druker BJ, Levine RL, Byrd JC, Foran JM. PMID: 36315007; PMCID: PMC10230164.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    13. PHASE II/III STUDY OF R-MINICHOP ± ORAL AZACITIDINE IN PARTICIPANTS AGE 75 YEARS OR OLDER WITH DIFFUSE LARGE B CELL AND RELATED LYMPHOMAS. Hematological Oncology. 2023 Jun 9; 41(S2):848-849. Brem BE, Li LH, Beaven BA, Caimi CP, Cerchietti CL, Olin OR, Henry HN, Dilon DH, Little LR, Leblanc LM, Kahl KB, Leonard LJ, Friedberg FJ, Smith SS. .
      View in: Publisher Site   Mentions:
    14. Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 05; 21(5):503-513. Pollyea DA, Altman JK, Assi R, Bixby D, Fathi AT, Foran JM, Gojo I, Hall AC, Jonas BA, Kishtagari A, Lancet J, Maness L, Mangan J, Mannis G, Marcucci G, Mims A, Moriarty K, Mustafa Ali M, Neff J, Nejati R, Olin R, Percival ME, Perl A, Przespolewski A, Rao D, Ravandi F, Shallis R, Shami PJ, Stein E, Stone RM, Sweet K, Thota S, Uy G, Vachhani P, Cassara CJ, Freedman-Cass DA, Stehman K. PMID: 37156478.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCells
    15. The Transplantation Ecosystem: A New Concept to Improve Access and Outcomes for Older Allogeneic Hematopoietic Cell Transplantation Patients. Transplant Cell Ther. 2023 Oct; 29(10):632.e1-632.e10. Wall SA, Olin R, Bhatt V, Chhabra S, Munshi P, Hacker E, Hashmi S, Hassel H, Howard D, Jayani R, Lin R, McCurdy S, Mishra A, Murthy H, Popat U, Wood W, Rosko AE, Artz A. PMID: 37137442.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    16. Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial. Cancer. 2023 08 01; 129(15):2308-2320. Duong VH, Ruppert AS, Mims AS, Borate U, Stein EM, Baer MR, Stock W, Kovacsovics T, Blum W, Arellano ML, Schiller GJ, Olin RL, Foran JM, Litzow MR, Lin TL, Patel PA, Foster MC, Redner RL, Al-Mansour Z, Cogle CR, Swords RT, Collins RH, Vergilio JA, Heerema NA, Rosenberg L, Yocum AO, Marcus S, Chen T, Druggan F, Stefanos M, Gana TJ, Shoben AB, Druker BJ, Burd A, Byrd JC, Levine RL, Boyiadzis MM. PMID: 37078412; PMCID: PMC11225573.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    17. Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma. Transplant Cell Ther. 2023 06; 29(6):350-355. Reyes KR, Huang CY, Lo M, Arora S, Chung A, Wong SW, Wolf J, Olin RL, Martin T, Shah N, Banerjee R. PMID: 36933659.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    18. Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial. Blood. 2023 03 16; 141(11):1265-1276. Daver NG, Dail M, Garcia JS, Jonas BA, Yee KWL, Kelly KR, Vey N, Assouline S, Roboz GJ, Paolini S, Pollyea DA, Tafuri A, Brandwein JM, Pigneux A, Powell BL, Fenaux P, Olin RL, Visani G, Martinelli G, Onishi M, Wang J, Huang W, Green C, Ott MG, Hong WJ, Konopleva MY, Andreeff M. PMID: 36265087; PMCID: PMC10651777.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    19. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need. Blood. 2023 02 09; 141(6):567-578. Pemmaraju N, Kantarjian H, Sweet K, Wang E, Senapati J, Wilson NR, Konopleva M, Frankel AE, Gupta V, Mesa R, Ulrickson M, Gorak E, Bhatia S, Budak-Alpdogan T, Mason J, Garcia-Romero MT, Lopez-Santiago N, Cesarman-Maus G, Vachhani P, Lee S, Bhatt VR, Blum W, Walter RB, Bixby D, Gojo I, Duvic M, Rampal RK, de Lima M, Foran J, Fathi AT, Hall AC, Jacoby MA, Lancet J, Mannis G, Stein AS, Mims A, Rizzieri D, Olin R, Perl A, Schiller G, Shami P, Stone RM, Strickland S, Wieduwilt MJ, Daver N, Ravandi F, Vasu S, Guzman M, Roboz GJ, Khoury J, Qazilbash M, Aung PP, Cuglievan B, Madanat Y, Kharfan-Dabaja MA, Pawlowska A, Taylor J, Tallman M, Dhakal P, Lane AA. PMID: 36399715.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    20. 304 HLA-DPB1 Mismatch Permissiveness and Activating KIR Haplotypes Have Different Impact on Allogeneic Hematopoietic Cell Transplant Survival Outcomes in Acute Leukemias and Myelodysplastic Syndrome. Transplantation and Cellular Therapy. 2023 Feb 1; 29(2):s232-s233. Lee LJ, Rajalingam RR, Kong KD, Ai AW, Andreadis AC, Damon DL, Dunavin DN, Gaensler GK, Kaplan KL, Martin MT, Olin OR, Sayre SP, Smith SC, Wolf WJ, Logan LA. .
      View in: Publisher Site   Mentions:
    21. Improved Gvhd and Relapse Free Survival Outcomes in Older Acute Leukemia Patients Receiving Young Haploidentical Donor Vs Older Matched Sibling Donor Reduced Intensity Conditioning Hematopoietic Cell Transplants. Blood. 2022 Nov 15; 140(Supplement 1):4895-4896. Tam TA, Logan LA, Choi CA, Fong FR, Damon DL, Olin OR, Dunavin DN, Sayre SP, Gaensler GK, Smith SC, Yan YL. .
      View in: Publisher Site   Mentions:
    22. Cancer and Aging. . 2022 Oct 21; 1-8. Rosko RA, Presley PC, Williams WG, Olin OR. .
      View in: Publisher Site   Mentions:
    23. Severe electrolyte derangements from lysozymuria in acute myeloid leukemia. EJHaem. 2022 Aug; 3(3):1018-1020. Pérez-Pinzón J, Olin RL, Banerjee R. PMID: 36051078; PMCID: PMC9421957.
      View in: PubMed   Mentions: 2  
    24. Geriatric assessment in adults age 50 years and older undergoing autologous hematopoietic cell transplantation for lymphoma. J Geriatr Oncol. 2022 06; 13(5):644-647. Kennedy VE, Huang CY, Kaplan LD, Andreadis C, Ai WZ, Olin RL. PMID: 35256304.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    25. Patterns and Predictors of Functional Decline after Allogeneic Hematopoietic Cell Transplantation in Older Adults. Transplant Cell Ther. 2022 06; 28(6):309.e1-309.e9. Huang LW, Sheng Y, Andreadis C, Logan AC, Mannis GN, Smith CC, Gaensler KML, Martin TG, Damon LE, Huang CY, Olin RL. PMID: 35247612; PMCID: PMC9198006.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    26. Transplantation for Older Adults-More Questions than Answers. Transplant Cell Ther. 2021 12; 27(12):955-956. McCurdy SR, Olin RL. PMID: 34895556.
      View in: PubMed   Mentions: 1     Fields:    
    27. S1918: A Phase II/III Randomized Study of R-Minichop with or without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements. Blood. 2021 Nov 5; 138(Supplement 1):3565-3565. Brem BE, Li LH, Beaven BA, Caimi CP, Cerchietti CL, Alizadeh AA, Olin OR, Henry HN, Dilon DH, Little LR, Laubach LC, Leblanc LM, Friedberg FJ, Smith SS. .
      View in: Publisher Site   Mentions:
    28. SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospective frailty tool. J Geriatr Oncol. 2022 03; 13(2):258-264. Brem EA, Li H, Beaven AW, Caimi PF, Cerchietti L, Alizadeh AA, Olin R, Henry NL, Dillon H, Little RF, Laubach C, LeBlanc M, Friedberg JW, Smith SM. PMID: 34686472; PMCID: PMC9879719.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    29. Haematopoietic stem-cell transplantation in older adults: geriatric assessment, donor considerations, and optimisation of care. Lancet Haematol. 2021 Nov; 8(11):e853-e861. Kennedy VE, Olin RL. PMID: 34624239.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    30. Physically "fit" for allogeneic stem cell transplant? Bone Marrow Transplant. 2021 11; 56(11):2628-2629. Jayani RV, Olin RL. PMID: 34400794; PMCID: PMC8365275.
      View in: PubMed   Mentions:    Fields:    
    31. Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis. Blood Cancer Discov. 2021 09; 2(5):434-449. Wang VE, Blaser BW, Patel RK, Behbehani GK, Rao AA, Durbin-Johnson B, Jiang T, Logan AC, Settles M, Mannis GN, Olin R, Damon LE, Martin TG, Sayre PH, Gaensler KM, McMahon E, Flanders M, Weinberg V, Ye CJ, Carbone DP, Munster PN, Fragiadakis GK, McCormick F, Andreadis C. PMID: 34514432; PMCID: PMC8425277.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    32. Breaking the Age Barrier: Physicians' Perceptions of Candidacy for Allogeneic Hematopoietic Cell Transplantation in Older Adults. Transplant Cell Ther. 2021 07; 27(7):617.e1-617.e7. Mishra A, Preussler JM, Bhatt VR, Bredeson C, Chhabra S, D'Souza A, Dahi PB, Hacker ED, Gowda L, Hashmi SK, Howard DS, Jakubowski A, Jayani R, Koll T, Lin RJ, Olin RL, Popat UR, Rodriguez C, Rosko A, Sabloff M, Sorror ML, Sung AD, Ustun C, Wood WA, Burns L, Artz A. PMID: 33836312; PMCID: PMC8254775.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    33. Reductions in vancomycin and meropenem following the implementation of a febrile neutropenia management algorithm in hospitalized adults: An interrupted time series analysis. Infect Control Hosp Epidemiol. 2021 09; 42(9):1090-1097. Trinh TD, Strnad L, Damon L, Dzundza JH, Graff LR, Griffith LM, Hilts-Horeczko A, Olin R, Shenoy S, DeVoe C, Wang L, Rodriguez-Monguio R, Gu TM, Hampton SR, Macapinlac BAC, Yang K, Doernberg SB. PMID: 33487182; PMCID: PMC8459315.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    34. Impact of Polypharmacy Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Older Adults. Transplant Cell Ther. 2021 04; 27(4):344.e1-344.e5. Sugidono M, Lo M, Young R, Rosario K, Jung Y, Huang CY, Sheng Y, Huang LW, Olin RL. PMID: 33836888.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    35. NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. J Natl Compr Canc Netw. 2021 01 06; 19(1):16-27. Pollyea DA, Bixby D, Perl A, Bhatt VR, Altman JK, Appelbaum FR, de Lima M, Fathi AT, Foran JM, Gojo I, Hall AC, Jacoby M, Lancet J, Mannis G, Marcucci G, Martin MG, Mims A, Neff J, Nejati R, Olin R, Percival ME, Prebet T, Przespolewski A, Rao D, Ravandi-Kashani F, Shami PJ, Stone RM, Strickland SA, Sweet K, Vachhani P, Wieduwilt M, Gregory KM, Ogba N, Tallman MS. PMID: 33406488.
      View in: PubMed   Mentions: 105     Fields:    Translation:Humans
    36. Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial. Blood. 2020 Nov 5; 136(Supplement 1):27-30. Stein SE, Huang HY, Borate BU, Baer BM, Stock SW, Kovacsovics KT, Blum BW, Schiller SG, Olin OR, Foran FJ, Litzow LM, Lin LT, Patel PP, Foster FM, Boyiadzis BM, Collins CR, Vergilio VJ, Heerema HN, Rosenberg RL, Yocum YA, Chen CT, Druggan DF, Marcus MS, Stefanos SM, Chervin CJ, Shoben SA, Druker DB, Burd BA, Byrd BJ, Levine LR, Mims MA. .
      View in: Publisher Site   Mentions:
    37. Excellent Outcomes Achieved with Medical Management of Chronic Phase CML Patients with Non-Hematologic TKI Intolerance. Blood. 2020 Nov 5; 136(Supplement 1):41-42. Schoenbeck SK, Tummala TS, Olin OR, Goyal GN, Dhruva DA, Damon DL, Logan LA, Smith SC, Shah SN. .
      View in: Publisher Site   Mentions:
    38. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nat Med. 2020 12; 26(12):1852-1858. Burd A, Levine RL, Ruppert AS, Mims AS, Borate U, Stein EM, Patel P, Baer MR, Stock W, Deininger M, Blum W, Schiller G, Olin R, Litzow M, Foran J, Lin TL, Ball B, Boyiadzis M, Traer E, Odenike O, Arellano M, Walker A, Duong VH, Kovacsovics T, Collins R, Shoben AB, Heerema NA, Foster MC, Vergilio JA, Brennan T, Vietz C, Severson E, Miller M, Rosenberg L, Marcus S, Yocum A, Chen T, Stefanos M, Druker B, Byrd JC. PMID: 33106665; PMCID: PMC8530434.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansCTClinical Trials
    39. Serial comprehensive geriatric and quality of life assessments in adults age ≥ 50 years undergoing autologous hematopoietic cell transplantation. J Geriatr Oncol. 2021 05; 12(4):531-539. Nawas MT, Sheng Y, Huang CY, Andreadis C, Martin TG, Wolf JL, Ai WZ, Kaplan LD, Mannis GN, Logan AC, Damon LE, Olin RL. PMID: 33059999.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    40. Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. Cancer. 2020 12 01; 126(23):5077-5087. Munshi PN, Vesole D, Jurczyszyn A, Zaucha JM, St Martin A, Davila O, Agrawal V, Badawy SM, Battiwalla M, Chhabra S, Copelan E, Kharfan-Dabaja MA, Farhadfar N, Ganguly S, Hashmi S, Krem MM, Lazarus HM, Malek E, Meehan K, Murthy HS, Nishihori T, Olin RL, Olsson RF, Schriber J, Seo S, Shah G, Solh M, Tay J, Kumar S, Qazilbash MH, Shah N, Hari PN, D'Souza A. PMID: 32965680; PMCID: PMC8063213.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    41. Multidisciplinary Management of Cancer During Pregnancy. JCO Oncol Pract. 2020 09; 16(9):545-557. Silverstein J, Post AL, Chien AJ, Olin R, Tsai KK, Ngo Z, Van Loon K. PMID: 32910882.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    42. Characterizing inclusion and exclusion criteria in clinical trials for chimeric antigen receptor (CAR) T-cell therapy among adults with hematologic malignancies. J Geriatr Oncol. 2021 03; 12(2):235-238. Jaggers JL, Giri S, Klepin HD, Wildes TM, Olin RL, Artz A, Wall S, Jaglowski S, William B, Benson DM, Rosko AE. PMID: 32855108.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    43. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Adv. 2020 07 14; 4(13):3180-3190. Zhou Z, Nath R, Cerny J, Wang HL, Zhang MJ, Abdel-Azim H, Agrawal V, Ahmed G, Al-Homsi AS, Aljurf M, Alkhateeb HB, Assal A, Bacher U, Bajel A, Bashir Q, Battiwalla M, Bhatt VR, Byrne M, Cahn JY, Cairo M, Choe H, Copelan E, Cutler C, Damlaj MB, DeFilipp Z, De Lima M, Diaz MA, Farhadfar N, Foran J, Freytes CO, Gerds AT, Gergis U, Grunwald MR, Gul Z, Hamadani M, Hashmi S, Hertzberg M, Hildebrandt GC, Hossain N, Inamoto Y, Isola L, Jain T, Kamble RT, Khan MW, Kharfan-Dabaja MA, Kebriaei P, Kekre N, Khera N, Lazarus HM, Liesveld JL, Litzow M, Liu H, Marks DI, Martino R, Mathews V, Mishra A, Murthy HS, Nagler A, Nakamura R, Nathan S, Nishihori T, Olin R, Olsson RF, Palmisiano N, Patel SS, Patnaik MM, Pawarode A, Perales MA, Politikos I, Popat U, Rizzieri D, Sandmaier BM, Savani BN, Seo S, Shah NN, Uy GL, Valcárcel D, Verdonck LF, Waller EK, Wang Y, Weisdorf D, Wirk B, Wong E, Yared JA, Saber W. PMID: 32663298; PMCID: PMC7362362.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    44. Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes. Blood Adv. 2020 06 23; 4(12):2810-2820. Olin RL, Fretham C, Pasquini MC, Arora M, Bhatt VR, Derman B, Giralt SA, Huang LW, Koll T, Lee SM, Lin RJ, Pang L, Popat UR, Weisdorf DJ, Artz A. PMID: 32574365; PMCID: PMC7322958.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    45. Early and sustained improvement in fatigue-related quality of life following red blood cell transfusion in outpatients. Qual Life Res. 2020 Oct; 29(10):2737-2744. Bruhn R, Karafin MS, Hilton JF, Kaidarova Z, Spencer BR, Qu L, Snyder EL, Olin R, Murphy EL, St Lezin E, NHLBI Recipient Epidemiology and Donor Evaluation Study (REDS)-III Program. PMID: 32382935; PMCID: PMC7572478.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    46. The Evolving Role of Transplant for Older Adults. . 2020 Jan 1; 613-629. Artz AA, Olin OR. .
      View in: Publisher Site   Mentions:
    47. Delivering intensive therapies to older adults with hematologic malignancies: strategies to personalize care. Hematology Am Soc Hematol Educ Program. 2019 12 06; 2019(1):63-70. Olin RL. PMID: 31808886; PMCID: PMC6913447.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    48. Delivering intensive therapies to older adults with hematologic malignancies: strategies to personalize care. Blood. 2019 12 05; 134(23):2013-2021. Olin RL. PMID: 31805199.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    49. Use of geriatric assessment in hematopoietic cell transplant. J Geriatr Oncol. 2020 03; 11(2):225-236. Jayani R, Rosko A, Olin R, Artz A. PMID: 31761694.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    50. Cognitive Impairment Is Associated with Inferior Survival and Increased Non-Relapse Mortality in Older Allogeneic Hematopoietic Cell Transplant (alloHCT) Recipients: A Multicenter Retrospective Study. Blood. 2019 Nov 13; 134(Supplement_1):4606-4606. Olin OR, Fretham FC, Pasquini PM, Arora AM, Bhatt BV, Derman DB, Giralt GS, Huang HL, Koll KT, Lee LS, Lin LR, Pang PL, Popat PU, Weisdorf WD, Artz AA. .
      View in: Publisher Site   Mentions:
    51. Characterizing Inclusion and Exclusion Criteria in Clinical Trials for CAR-T Cellular Therapy Among Adults with Hematologic Malignancies. Blood. 2019 Nov 13; 134(Supplement_1):5819-5819. Jaggers JJ, Klepin KH, Wildes WT, Olin OR, Artz AA, Wall WS, Jaglowski JS, William WB, Benson BD, Rosko RA. .
      View in: Publisher Site   Mentions:
    52. Efficacy of Venetoclax Combination Therapy with Hypomethylating Agents in Patients with Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation. Blood. 2019 Nov 13; 134(Supplement_1):5089-5089. Mittal MV, Lo LM, Damon DL, Gaensler GK, Martin MT, Olin OR, Smith SC, Logan LA. .
      View in: Publisher Site   Mentions:
    53. Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative Neoplasms. Blood. 2019 Nov 13; 134(Supplement_1):1165-1165. Schoenbeck SK, Salmasi SG, Cerejo CM, Cornett CP, Damon DL, Logan LA, Olin OR, Leavitt LA, Smith SC. .
      View in: Publisher Site   Mentions:
    54. Symptom Assessment in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms at an Academic Medical Institution. Blood. 2019 Nov 13; 134(Supplement_1):5859-5859. Schoenbeck SK, Cerejo CM, Cornett CP, Damon DL, Gaensler GK, Leavitt LA, Logan LA, Mannis MG, Olin OR, Salmasi SG, Sayre SP, Shah SN, Dhruva DA, Atreya AC, Smith SC. .
      View in: Publisher Site   Mentions:
    55. A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS). Blood. 2019 Nov 13; 134(Supplement_1):3932-3932. DiNardo DC, Olin OR, Ishizawa IJ, Sumi SH, Xie XJ, Kato KK, Kumar KP, Andreeff AM. .
      View in: Publisher Site   Mentions:
    56. Precision Medicine Treatment in Older AML: Results of Beat AML Master Trial. Blood. 2019 Nov 13; 134(Supplement_1):175-175. Burd BA, Levine LR, Ruppert RA, Mims MA, Borate BU, Stein SE, Patel PP, Baer BM, Stock SW, Deininger DM, Blum BW, Schiller SG, Olin OR, Litzow LM, Foran FJ, Lin LT, Ball BB, Boyiadzis BM, Traer TE, Odenike OO, Arellano AM, Walker WA, Duong DV, Collins CR, Heerema HN, Vergilio VJ, Brennan BT, Vietz VC, Vittorio VM, Rosenberg RL, Marcus MS, Yocum YA, Stefanos SM, Druker DB, Byrd BJ. .
      View in: Publisher Site   Mentions:
    57. Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy. Blood. 2019 Nov 13; 134(Supplement_1):229-229. Daver DN, Garcia GJ, Jonas JB, Kelly KK, Assouline AS, Brandwein BJ, Fenaux FP, Olin OR, Martinelli MG, Paolini PS, Pigneux PA, Pollyea PD, Powell PB, Roboz RG, Tafuri TA, Vey VN, Visani VG, Yee YK, Dail DM, Green GC, Kirschbrown KW, Hong HW, Ott OM, Onishi OM, Wang WJ, Konopleva KM, Andreeff AM. .
      View in: Publisher Site   Mentions:
    58. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med. 2019 10 31; 381(18):1728-1740. Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, Montesinos P, Baer MR, Larson RA, Ustun C, Fabbiano F, Erba HP, Di Stasi A, Stuart R, Olin R, Kasner M, Ciceri F, Chou WC, Podoltsev N, Recher C, Yokoyama H, Hosono N, Yoon SS, Lee JH, Pardee T, Fathi AT, Liu C, Hasabou N, Liu X, Bahceci E, Levis MJ. PMID: 31665578.
      View in: PubMed   Mentions: 491     Fields:    Translation:HumansCTClinical Trials
    59. 1089. Implementation of a Febrile Neutropenia Management Algorithm on Antibiotic Use and Outcomes: An Interrupted Time Series Analysis. Open Forum Infectious Diseases. 2019 Oct 23; 6(Suppl 2):s386-s387. Trinh TT, Strnad SL, Damon DL, Dzundza DJ, Graff GL, Griffith GL, Hilts-Horeczko HA, Olin OR, Shenoy SS, DeVoe DC, Wang WL, Rodriguez-Monguio RR, Doernberg DS. .
      View in: Publisher Site   Mentions:
    60. Functional Status as Measured by Geriatric Assessment Predicts Inferior Survival in Older Allogeneic Hematopoietic Cell Transplantation Recipients. Biol Blood Marrow Transplant. 2020 01; 26(1):189-196. Huang LW, Sheng Y, Andreadis C, Logan AC, Mannis GN, Smith CC, Gaensler KML, Martin TG, Damon LE, Steinman MA, Huang CY, Olin RL. PMID: 31493541; PMCID: PMC6942208.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    61. Inflammatory biomarkers and patient-reported outcomes in acute myeloid leukemia: Refocusing on older adults. J Geriatr Oncol. 2020 04; 11(3):395-398. Huang LW, Olin RL. PMID: 31350219; PMCID: PMC7006625.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    62. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Adv. 2019 06 25; 3(12):1826-1836. Rashidi A, Hamadani M, Zhang MJ, Wang HL, Abdel-Azim H, Aljurf M, Assal A, Bajel A, Bashey A, Battiwalla M, Beitinjaneh AM, Bejanyan N, Bhatt VR, Bolaños-Meade J, Byrne M, Cahn JY, Cairo M, Ciurea S, Copelan E, Cutler C, Daly A, Diaz MA, Farhadfar N, Gale RP, Ganguly S, Grunwald MR, Hahn T, Hashmi S, Hildebrandt GC, Holland HK, Hossain N, Kanakry CG, Kharfan-Dabaja MA, Khera N, Koc Y, Lazarus HM, Lee JW, Maertens J, Martino R, McGuirk J, Munker R, Murthy HS, Nakamura R, Nathan S, Nishihori T, Palmisiano N, Patel S, Pidala J, Olin R, Olsson RF, Oran B, Ringden O, Rizzieri D, Rowe J, Savoie ML, Schultz KR, Seo S, Shaffer BC, Singh A, Solh M, Stockerl-Goldstein K, Verdonck LF, Wagner J, Waller EK, De Lima M, Sandmaier BM, Litzow M, Weisdorf D, Romee R, Saber W. PMID: 31201170; PMCID: PMC6595262.
      View in: PubMed   Mentions: 52     Fields:    Translation:Humans
    63. Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 06 01; 17(6):721-749. Tallman MS, Wang ES, Altman JK, Appelbaum FR, Bhatt VR, Bixby D, Coutre SE, De Lima M, Fathi AT, Fiorella M, Foran JM, Hall AC, Jacoby M, Lancet J, LeBlanc TW, Mannis G, Marcucci G, Martin MG, Mims A, O'Donnell MR, Olin R, Peker D, Perl A, Pollyea DA, Pratz K, Prebet T, Ravandi F, Shami PJ, Stone RM, Strickland SA, Wieduwilt M, Gregory KM, OCN, Hammond L, Ogba N. PMID: 31200351.
      View in: PubMed   Mentions: 206     Fields:    Translation:Humans
    64. Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results. Clin Cancer Res. 2019 08 15; 25(16):4917-4923. Wieduwilt MJ, Pawlowska N, Thomas S, Olin R, Logan AC, Damon LE, Martin T, Kang M, Sayre PH, Boyer W, Gaensler KML, Anderson K, Munster PN, Andreadis C. PMID: 31152020.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCellsCTClinical Trials
    65. Updates on Hematologic Malignancies in the Older Adult: Focus on Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, and Multiple Myeloma. Curr Oncol Rep. 2019 03 08; 21(4):35. Huang LW, Wong SW, Andreadis C, Olin RL. PMID: 30848394; PMCID: PMC6438699.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    66. Limitation in Patient-Reported Function Is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 06; 25(6):1218-1224. Nawas MT, Andreadis C, Martin TG, Wolf JL, Ai WZ, Kaplan LD, Mannis GN, Logan AC, Damon LE, Huang CY, Olin RL. PMID: 30708189.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    67. Safety, Efficacy, Pharmacokinetic (PK) and Biomarker Analyses of BCL2 Inhibitor Venetoclax (Ven) Plus MDM2 Inhibitor Idasanutlin (idasa) in Patients (pts) with Relapsed or Refractory (R/R) AML: A Phase Ib, Non-Randomized, Open-Label Study. Blood. 2018 Nov 29; 132(Supplement 1):767-767. Daver DN, Pollyea PD, Garcia GJ, Jonas JB, Yee YK, Fenaux FP, Assouline AS, Vey VN, Olin OR, Roboz RG, Tafuri TA, Visani VG, Kirschbrown KW, Green GC, Ma MC, Dail DM, Wang WJ, Ott OM, Mobasher MM, Phuong PP, Hong HW, Konopleva KM, Andreeff AM. .
      View in: Publisher Site   Mentions:
    68. Functional Status Is Associated with Outcomes after Allogeneic Stem Cell Transplantation for Older Patients with Hematologic Malignancies. Blood. 2018 Nov 29; 132(Supplement 1):3599-3599. Huang HL, Huang HC, Andreadis AC, Logan LA, Mannis MG, Smith SC, Gaensler GK, Martin MT, Damon DL, Steinman SM, Olin OR. .
      View in: Publisher Site   Mentions:
    69. Efficacy and cost-effectiveness of clofarabine with high-dose cytarabine for treatment of relapsed/refractory acute myeloid leukemia (R/R AML). Journal of Clinical Oncology. 2018 May 20; 36(15_suppl):e19009-e19009. Nunnery NS, Wang WD, Tan TM, Fong FR, Lo LM, Olin OR. .
      View in: Publisher Site   Mentions:
    70. Impact of patient reported functional limitation on overall survival in older adults undergoing autologous hematopoietic cell transplant (AutoHCT). Journal of Clinical Oncology. 2018 May 20; 36(15_suppl):10030-10030. Nawas NM, Andreadis AC, Martin MT, Wolf WJ, Ai AW, Kaplan KL, Mannis MG, Logan LA, Damon DL, Huang HC, Olin OR. .
      View in: Publisher Site   Mentions:
    71. A call to action in hematologic disorders: A report from the ASH scientific workshop on hematology and aging. J Geriatr Oncol. 2018 07; 9(4):287-290. Rosko AE, Olin RL, Artz A, Wildes TM, Stauder R, Klepin HD. PMID: 29759912; PMCID: PMC6619431.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    72. The Evolving Role of Transplant for Older Adults. Geriatric Oncology. 2018 Jan 1; 1-17. Artz AA, Olin OR. .
      View in: Publisher Site   Mentions:
    73. Emerging therapeutic modalities for acute myeloid leukemia (AML) in older adults. J Geriatr Oncol. 2017 Nov; 8(6):417-420. Huang LW, Olin RL. PMID: 28835351; PMCID: PMC5936484.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    74. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 2017 08 31; 130(9):1156-1164. Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, Aljurf M, Ballen KK, Bajel A, Baron F, Battiwalla M, Beitinjaneh A, Cahn JY, Carabasi M, Chen YB, Chhabra S, Ciurea S, Copelan E, D'Souza A, Edwards J, Foran J, Freytes CO, Fung HC, Gale RP, Giralt S, Hashmi SK, Hildebrandt GC, Ho V, Jakubowski A, Lazarus H, Luskin MR, Martino R, Maziarz R, McCarthy P, Nishihori T, Olin R, Olsson RF, Pawarode A, Peres E, Rezvani AR, Rizzieri D, Savani BN, Schouten HC, Sabloff M, Seftel M, Seo S, Sorror ML, Szer J, Wirk BM, Wood WA, Artz A. PMID: 28674027; PMCID: PMC5580273.
      View in: PubMed   Mentions: 103     Fields:    Translation:Humans
    75. Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 07; 15(7):926-957. O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Bhatt V, Bixby D, Blum W, Coutre SE, De Lima M, Fathi AT, Fiorella M, Foran JM, Gore SD, Hall AC, Kropf P, Lancet J, Maness LJ, Marcucci G, Martin MG, Moore JO, Olin R, Peker D, Pollyea DA, Pratz K, Ravandi F, Shami PJ, Stone RM, Strickland SA, Wang ES, Wieduwilt M, Gregory K, Ogba N. PMID: 28687581.
      View in: PubMed   Mentions: 163     Fields:    Translation:Humans
    76. CyFi: A phase I study exploring the role of cMET pathway inhibition with ficlatuzumab (Fi) combined with high-dose cytarabine (Cy) in patients with high risk relapsed or refractory acute myeloid leukemia (AML). Journal of Clinical Oncology. 2017 May 20; 35(15_suppl):7040-7040. Wang WV, Mannis MG, Olin OR, Logan LA, Martin MT, Damon DL, Kilayko KD, Munster MP, Andreadis AC. .
      View in: Publisher Site   Mentions:
    77. Hematopoietic cell transplantation: Is there any age limit?. Hematopoietic Cell Transplants. 2017 Jan 1; 51-58. Artz AA, Olin OR. .
      View in: Publisher Site   Mentions:
    78. Phase 1 Dose Escalation Study of MDM2 Inhibitor DS-3032b in Patients with Hematological Malignancies - Preliminary Results. Blood. 2016 Dec 2; 128(22):593-593. DiNardo DC, Rosenthal RJ, Andreeff AM, Zernovak ZO, Kumar KP, Gajee GR, Chen CS, Rosen RM, Song SS, Kochan KJ, Limsakun LT, Olin OR. .
      View in: Publisher Site   Mentions:
    79. Geriatric assessment with management in cancer care: Current evidence and potential mechanisms for future research. J Geriatr Oncol. 2016 07; 7(4):242-8. Magnuson A, Allore H, Cohen HJ, Mohile SG, Williams GR, Chapman A, Extermann M, Olin RL, Targia V, Mackenzie A, Holmes HM, Hurria A. PMID: 27197915; PMCID: PMC4969156.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    80. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Cancer. 2016 06 15; 122(12):1871-9. Borthakur G, Popplewell L, Boyiadzis M, Foran J, Platzbecker U, Vey N, Walter RB, Olin R, Raza A, Giagounidis A, Al-Kali A, Jabbour E, Kadia T, Garcia-Manero G, Bauman JW, Wu Y, Liu Y, Schramek D, Cox DS, Wissel P, Kantarjian H. PMID: 26990290; PMCID: PMC5779863.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansCellsCTClinical Trials
    81. Biased and unbiased estimation in longitudinal studies with informative visit processes. Biometrics. 2016 12; 72(4):1315-1324. McCulloch CE, Neuhaus JM, Olin RL. PMID: 26990830; PMCID: PMC5026863.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    82. Improving venous thromboembolism (VTE) prophylaxis for hospitalized malignant hematology/bone marrow transplant (heme/BMT) patients. Journal of Clinical Oncology. 2016 Mar 1; 34(7_suppl):79-79. Wong WM, Dzundza DJ, Ajmera AA, Gustafson GA, Lo LM, Fong FR, Graff GL, Dao DB, Young YR, Damon DL, Martin MT, Olin OR. .
      View in: Publisher Site   Mentions:
    83. Comprehensive Genomic Profiling of Diagnostic Bone Marrow Specimens Identifies Mutational Profiles Predictive of Relapse in Patients with Acute Myeloid Leukemia Who Undergo Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 2016 Mar 1; 22(3):s41-s42. Mannis MG, Zhong ZS, Nahas NM, Kahira KL, Logan LA, Andreadis AC, Damon DL, Olin OR, Balasubramanian BS, He HJ, Vergilio VJ, Mughal MT, Ai AW, Gaensler GK, Sayre SP, Wolf WJ, Martin MT. .
      View in: Publisher Site   Mentions:
    84. Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 06; 22(6):1030-1036. Mannis GN, Martin TG, Damon LE, Andreadis C, Olin RL, Kong KA, Faham M, Hwang J, Ai WZ, Gaensler KML, Sayre PH, Wolf JL, Logan AC. PMID: 26899561.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    85. Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission. Leuk Lymphoma. 2016 07; 57(7):1560-6. Mannis GN, Martin TG, Damon LE, Logan AC, Olin RL, Flanders MD, Ai WZ, Gaensler KM, Kaplan LD, Sayre PH, Smith CC, Wolf JL, Andreadis C. PMID: 26490487.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    86. Comorbidity in older adults with cancer. J Geriatr Oncol. 2016 07; 7(4):249-57. Williams GR, Mackenzie A, Magnuson A, Olin R, Chapman A, Mohile S, Allore H, Somerfield MR, Targia V, Extermann M, Cohen HJ, Hurria A, Holmes H. PMID: 26725537; PMCID: PMC4917479.
      View in: PubMed   Mentions: 101     Fields:    Translation:Humans
    87. Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk Following Autologous Hematopoietic Cell Transplantation. Blood. 2015 Dec 3; 126(23):1420-1420. Mannis MG, Martin MT, Damon DL, Andreadis AC, Olin OR, Kong KK, Faham FM, Ai AW, Gaensler GK, Sayre SP, Wolf WJ, Logan LA. .
      View in: Publisher Site   Mentions:
    88. Panobinostat-Augmented Cytarabine and Daunorubicin (7+3) Induction for Older Patients with AML or High-Risk MDS Is Well Tolerated and Results in Favorable Clinical Outcomes: The Panda Trial. Blood. 2015 Dec 3; 126(23):1337-1337. Wieduwilt WM, Thomas TS, Olin OR, Logan LA, Damon DL, Martin MT, Kang KM, Sayre SP, Boyer BW, Gaensler GK, Anderson AK, Munster MP, Andreadis AC. .
      View in: Publisher Site   Mentions:
    89. Increased risk of second malignant neoplasms in adolescents and young adults with cancer. Cancer. 2016 Jan 01; 122(1):116-23. Lee JS, DuBois SG, Coccia PF, Bleyer A, Olin RL, Goldsby RE. PMID: 26441212.
      View in: PubMed   Mentions: 64     Fields:    Translation:Humans
    90. A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15(6):377-83. Mannis GN, Andreadis C, Logan AC, Damon LE, Benet LZ, Ai WZ, Gaensler KM, Kaplan LD, Koplowicz YB, Linker CA, Olin RL, Sayre PH, Smith CC, Sudhindra A, Venstrom JM, Wolf JL, Martin TG. PMID: 25776193.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    91. Long-Term Outcomes of 133 Patients with Intermediate-Risk Acute Myeloid Leukemia Treated with High-Dose Chemotherapy and Autologous Stem Cell Rescue in First Complete Remission. Biology of Blood and Marrow Transplantation. 2015 Feb 1; 21(2):s141-s142. Mannis MG, Martin MT, Damon DL, Logan LA, Ai AW, Gaensler GK, Kaplan KL, Mahindra MA, Olin OR, Sayre SP, Smith SC, Wolf WJ, Hwang HJ, Andreadis AC. .
      View in: Publisher Site   Mentions:
    92. Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis. Bone Marrow Transplant. 2015 Jan; 50(1):40-4. Mannis GN, Logan AC, Leavitt AD, Yanada M, Hwang J, Olin RL, Damon LE, Andreadis C, Ai WZ, Gaensler KM, Greene CC, Gupta NK, Kaplan LD, Mahindra A, Miyazaki Y, Naoe T, Ohtake S, Sayre PH, Smith CC, Venstrom JM, Wolf JL, Caballero L, Emi N, Martin TG. PMID: 25243620.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    93. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients. J Geriatr Oncol. 2014 Jul; 5(3):238-44. Keller JW, Andreadis C, Damon LE, Kaplan LD, Martin TG, Wolf JL, Ai WZ, Venstrom JM, Smith CC, Gaensler KM, Hwang J, Olin RL. PMID: 24894413.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    94. Comprehensive Geriatric Assessment Identifies Significant Functional Impairments in Older Hematopoietic Cell Transplant Recipients. Biology of Blood and Marrow Transplantation. 2014 Feb 1; 20(2):s65-s66. Olin OR, Andreadis AC, Martin MT, Wolf WJ, Kaplan KL, Ai AW, Venstrom VJ, Logan LA, Smith SC, Gaensler GK, Hwang HJ, Damon DL. .
      View in: Publisher Site   Mentions:
    95. A Phase 1 Study of Targeted, Dose-Escalated Intravenous Busulfan in Combination with Etoposide As Preparative Therapy for Autologous Stem Cell Transplant in Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation. 2014 Feb 1; 20(2):s114-s115. Mannis MG, Damon DL, Ai AW, Andreadis AC, Gaensler GK, Kaplan KL, Logan LA, Mahindra MA, Olin OR, Sayre SP, Smith SC, Venstrom VJ, Wolf WJ, Martin MT. .
      View in: Publisher Site   Mentions:
    96. Delayed Hematopoietic Recovery After Autologous Stem Cell Transplantation In Patients Receiving Arsenic Trioxide-Based Therapy For Acute Promyelocytic Leukemia. Blood. 2013 Nov 15; 122(21):2172-2172. Mannis MG, Damon DL, Ai AW, Andreadis AC, Gaensler GK, Gupta GN, Kaplan KL, Leavitt LA, Logan LA, Olin OR, Sayre SP, Smith SC, Venstrom VJ, Martin MT. .
      View in: Publisher Site   Mentions:
    97. David versus Goliath: decision analysis predicts results of a large clinical trial in follicular lymphoma. J Clin Oncol. 2013 Oct 01; 31(28):3608-9. Olin RL, Andreadis C. PMID: 23980082.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    98. Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Is Predictive of Serious Adverse Events and Overall Survival in Older Allogeneic Transplant Recipients. Biology of Blood and Marrow Transplantation. 2013 Feb 1; 19(2):s293-s294. Keller KJ, Damon DL, Kaplan KL, Martin MT, Wolf WJ, Ai AW, Andreadis AC, Venstrom VJ, Smith SC, Gaensler GK, Hwang HJ, Olin OR. .
      View in: Publisher Site   Mentions:
    99. Phase I/II Trial of the MEK1/2 Inhibitor Trametinib (GSK1120212) in Relapsed/Refractory Myeloid Malignancies: Evidence of Activity in Patients with RAS Mutation-Positive Disease. Blood. 2012 Nov 16; 120(21):677-677. Borthakur BG, Popplewell PL, Boyiadzis BM, Foran FJ, Platzbecker PU, Vey VN, Roland RW, Olin OR, Raza RA, Giagounidis GA, Ottmann OO, Al-Kali AA, Jabbour JE, Kadia KT, Garcia-Manero GG, Bauman BJ, Wu WY, Liu LY, Schramek SD, Zhu ZJ, Wissel WP, Kantarjian KH. .
      View in: Publisher Site   Mentions:
    100. Determinants of the optimal first-line therapy for follicular lymphoma: a decision analysis. Am J Hematol. 2010 Apr; 85(4):255-60. Olin RL, Kanetsky PA, Ten Have TR, Nasta SD, Schuster SJ, Andreadis C. PMID: 20196173; PMCID: PMC2932442.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    101. Allogeneic Transplantation for the Treatment of Multiple Myeloma. Allogeneic Stem Cell Transplantation. 2010 Jan 1; 261-279. Olin OR, Vogl VD, Stadtmauer SE. .
      View in: Publisher Site   Mentions:
    102. Choosing First-Line Therapy for Follicular Lymphoma (FL): A Decision Analysis. Blood. 2008 Nov 16; 112(11):670-670. Olin OR, Kanetsky KP, Have HT, Nasta NS, Schuster SS, Andreadis AC. .
      View in: Publisher Site   Mentions:
    103. The Impact of Rituximab Resistance on Overall Survival Rate in Low-Grade Follicular Lymphoma. Blood. 2008 Nov 16; 112(11):3783-3783. Abdollahi AS, Chong CE, Olin OR, Nasta NS, Andreadis AC, Stadtmauer SE, Lake LC, Downs DL, Schuster SS. .
      View in: Publisher Site   Mentions:
    104. Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplant. 2009 Mar; 43(5):417-22. Olin RL, Vogl DT, Porter DL, Luger SM, Schuster SJ, Tsai DE, Siegel DL, Cook RJ, Mangan PA, Cunningham K, Stadtmauer EA. PMID: 18850013; PMCID: PMC2757257.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    105. Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis. Am J Hematol. 2008 Sep; 83(9):747-9. Olin RL, Nichols KE, Naghashpour M, Wasik M, Shelly B, Stadtmauer EA, Vogl DT. PMID: 18615554; PMCID: PMC2757271.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    106. Non-myopathic cardiac events in two patients treated with trastuzumab. Breast J. 2007 Mar-Apr; 13(2):211-2. Olin RL, Desai SS, Fox K, Davidson R. PMID: 17319871.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    107. Second Autologous Stem Cell Transplant (ASCT) as Salvage Therapy for Relapsed Multiple Myeloma. Blood. 2005 Nov 16; 106(11):1170-1170. Olin OR, Porter PD, Luger LS, Schuster SS, Tsai TD, Nasta NS, Perl PA, Loren LA, Goldstein GS, Glatstein GE, Siegel SD, Vogl VD, Mangan MP, Cunningham CK, Stadtmauer SE. .
      View in: Publisher Site   Mentions:
    108. Pegfilgrastim versus filgrastim to accelerate hematopoietic recovery after high-dose melphalan and autologous hematopoietic stem cell transplantation (ASCT) for multiple myeloma. Biology of Blood and Marrow Transplantation. 2005 Feb 1; 11(2):87. Olin OR, Luger LS, Porter PD, Schuster SS, Tsai TD, Nasta NS, Perl PA, Loren LA, Goldstein GS, Mangan MP, Sherry SV, Cunningham CK, Sachs SB, Hummel HK, Stadtmauer SE. .
      View in: Publisher Site   Mentions:
    109. Pegfilgrastim Versus Filgrastim To Accelerate Hematopoietic Recovery after High Dose Melphalan and Autologous Hematopoietic Stem Cell Transplant (ASCT) for Multiple Myeloma. Blood. 2004 Nov 16; 104(11):5193-5193. Olin OR, Luger LS, Porter PD, Schuster SS, Tsai TD, Nasta NS, Perl PA, Loren LA, Goldstein GS, Mangan MP, Sherry SV, Cunningham CK, Sachs SB, Hummel HK, Stadtmauer SE. .
      View in: Publisher Site   Mentions:
    Rebecca's Networks
    Concepts (230)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (57)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.